Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction with the Hypomethylating Agent Azacitidine in Patients with Advanced Pancreatic Cancer After Failure of First-Line Therapy
Study of Drug in Patients with Advanced Pancreatic Cancer After Failure of First-Line Therapy
Sponsor: Merck & Co., Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR3554
U.S. Govt. ID: NCT03264404
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine the effectiveness of combining immune therapy, pembrolizumab, with a hypomethylating agent, azacitidine, for pancreatic cancer. People who have advanced pancreatic cancer with disease progression on first-line therapy are usually treated with a second chemotherapy regimen. However, there is no single accepted chemotherapy regimen and national guidelines recommend chemotherapy or clinical trial participation. In this study, all study subjects will receive a combination of immune therapy (every 3 weeks) and a hypomethylating agent (every 4 weeks).
This study is closed
Investigator
Susan Bates, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with pancreatic adenocarcinoma? Yes No
Do you have a predicted life expectancy of greater than 3 months? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162